(Reuters) – A large British study looking into potential early-stage COVID-19 treatments will begin testing gout medication colchicine and has widened enrolment criteria for the arm of the trial, University of Oxford researchers said on Wednesday.
The anti-inflammatory drug is already being tested in another UK study dubbed RECOVERY, which is the world’s largest clinical trial of treatments for patients hospitalised with COVID-19.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D’Silva)
